Sign in or create an account to add this stock to your watchlist.
About OptiNose (NASDAQ:OPTN)
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPTN
CUSIPN/A
Phone267-364-3500
Debt
Debt-to-Equity Ratio0.57
Current Ratio9.66
Quick Ratio9.50
Price-To-Earnings
Trailing P/E Ratio-4.31
Forward P/E Ratio-7.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$47.50 million
Price / Sales19.52
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book5.96
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees82
Outstanding Shares38,010,000
OptiNose (NASDAQ:OPTN) Frequently Asked Questions
What is OptiNose's stock symbol?
OptiNose trades on the NASDAQ under the ticker symbol "OPTN."
How were OptiNose's earnings last quarter?
OptiNose (NASDAQ:OPTN) posted its earnings results on Monday, May, 14th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.07. The business had revenue of $0.87 million for the quarter. View OptiNose's Earnings History.
What price target have analysts set for OPTN?
4 brokerages have issued 1-year price objectives for OptiNose's stock. Their predictions range from $27.00 to $33.00. On average, they anticipate OptiNose's stock price to reach $29.25 in the next twelve months. View Analyst Ratings for OptiNose.
Who are some of OptiNose's key competitors?
Some companies that are related to OptiNose include Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO) and Heron Therapeutics (HRTX).
Who are OptiNose's key executives?
OptiNose's management team includes the folowing people:
- Mr. Peter K. Miller, CEO & Director (Age 57)
- Dr. Ramy A. Mahmoud, Pres and Chief Operating Officer (Age 53)
- Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 46)
- Mr. Keith Alan Goldan, Chief Financial Officer (Age 47)
- Ms. Ricci Whitlow, VP of Technical Operations
When did OptiNose IPO?
(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.
When did OptiNose's lock-up period expire?
OptiNose's lock-up period expired on Wednesday, April 11th. OptiNose had issued 7,500,000 shares in its IPO on October 13th. The total size of the offering was $120,000,000 based on an initial share price of $16.00. Since the expiration of OptiNose's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Has OptiNose been receiving favorable news coverage?
Headlines about OPTN stock have been trending somewhat negative recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OptiNose earned a daily sentiment score of 0.00 on Accern's scale. They also assigned media headlines about the company an impact score of 47.98 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are OptiNose's major shareholders?
OptiNose's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (1.83%), Foresite Capital Management IV LLC (1.28%), Asymmetry Capital Management L.P. (0.89%), Next Century Growth Investors LLC (0.41%), American Century Companies Inc. (0.28%) and Neuberger Berman Group LLC (0.26%). View Institutional Ownership Trends for OptiNose.
Which institutional investors are selling OptiNose stock?
Which institutional investors are buying OptiNose stock?
OPTN stock was acquired by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Tamarack Advisers LP, Next Century Growth Investors LLC, Asymmetry Capital Management L.P., Foresite Capital Management IV LLC, American Century Companies Inc. and Northern Trust Corp. View Insider Buying and Selling for OptiNose.
How do I buy shares of OptiNose?
Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OptiNose's stock price today?
One share of OPTN stock can currently be purchased for approximately $24.39.
How big of a company is OptiNose?
OptiNose has a market capitalization of $914.44 million and generates $47.50 million in revenue each year. The company earns $-48,900,000.00 in net income (profit) each year or ($5.63) on an earnings per share basis. OptiNose employs 82 workers across the globe.
How can I contact OptiNose?
OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]
MarketBeat Community Rating for OptiNose (OPTN)
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
OptiNose (NASDAQ:OPTN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for OptiNose in the last 12 months. Their average twelve-month price target is $29.25, suggesting that the stock has a possible upside of 19.93%. The high price target for OPTN is $33.00 and the low price target for OPTN is $27.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $29.25 | $29.25 | $29.25 | $29.00 |
| Price Target Upside: | 19.93% upside | 47.21% upside | 47.21% upside | 39.69% upside |
OptiNose (NASDAQ:OPTN) Consensus Price Target History
OptiNose (NASDAQ:OPTN) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
OptiNose (NASDAQ:OPTN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
OptiNose (NASDAQ OPTN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 67.80%
Institutional Ownership Percentage: 29.63%
OptiNose (NASDAQ OPTN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2018 | Peter K Miller | CEO | Buy | 5,054 | $18.58 | $93,903.32 | |  |
(Data available from 1/1/2013 forward)
OptiNose (NASDAQ OPTN) News Headlines
| Source: |
|
OptiNose (NASDAQ:OPTN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
OptiNose (NASDAQ:OPTN) Income Statement, Balance Sheet and Cash Flow Statement
OptiNose (NASDAQ OPTN) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
